Podcast

Running Interference: RNAi With Silence Therapeutics' Craig Tooman

Source: Cytiva
22_01_bpo_busbiotech_social_ep97

Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of RNAi gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease to rare diseases. 

          

 

 

LISTEN TO THE PODCAST!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Laboratory Network? Subscribe today.

Subscribe to Laboratory Network X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Laboratory Network